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national estimates were higher than reported from other countries. Further research 
at the provincial level is forthcoming to validate the national estimates.
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Objectives: Persistent asthma is a significant, understudied health condition lead-
ing to disproportionate use of health care resources and patient burden compared 
to patients with mild-to-moderate forms of the disease. . This study was designed 
to describe the population of individuals with persistent asthma and severe per-
sistent asthma in the U.S., identify asthma medication use patterns, and examine 
the influence of patient characteristics on choice of treatment. MethOds: We used 
HEDIS criteria to identify individuals with persistent asthma in the 2011 Medical 
Expenditure Panel Survey. Asthma severity was assessed based on exacerbations 
and prescription medication use. Andersen’s behavioral model of health service 
use was used to identify predisposing, enabling, and need variables associated with 
persistent asthma and medication use. Results: The persistent asthma popula-
tion (n= 566) was predominantly female (67.72%) and white (83.69%), with a mean 
age of 53.06 years. On average, they had 0.16 ER visits, 0.047 hospital stays, 0.18 
outpatient visits, 1.47 office-based provider visits, and 10.32 prescription medica-
tion fills during the survey year. 2.3% of patients were identified as having severe 
persistent asthma. They were predominantly female (92%) and white (81.46%), with 
a mean age of 58.08 years. They had an average of 0.54 ER visits, 0.54 hospital stays, 
0.154 outpatient visits, 3 office-based provider encounters, and 25.92 prescription 
medication fills during the survey year. 41.83% of the persistent asthma population 
were not prescribed a short-acting beta agonist, compared to 36.71% of the severe 
asthma population. 49.85% of the persistent asthma population was on an inhaled 
corticosteroid + long-acting beta agonist (ICS/LABA), per guideline recommenda-
tions. cOnclusiOns: There appear to be patient characteristics that are associated 
with persistent asthma; however the lack sample size in the severe population lim-
ited results. A significant number of people were not treated according to guidelines, 
indicating a potential deficit in prescribing practices.
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Objectives: The goal of this study was to examine patient age and gender as 
well as racial and geographic variations in asthma prevalence among U.S. Medicaid 
patients. MethOds: Patients diagnosed with asthma (International Classification 
of Disease, 9th Revision, Clinical Modification [ICD-9-CM] diagnosis code 493.xx) 
were included in a retrospective study (January 1, 2008 to December 31, 2009) from a 
Medicaid fee-for-service (FFS) population. All patients were required to have a 2-year 
continuous Medicaid FFS enrollment in 2008 and 2009. Patients with managed care 
enrollment in any month during the study period were excluded. Disease prevalence 
was stratified by region, state, age, gender and race for all the patients. Descriptive 
statistics were calculated as the number and percentage of patients in each category 
to measure the prevalence in the sample. Results: A total of 399,572 patients were 
diagnosed with asthma in 2008 and 2009. For asthma patients, prevalence was the 
highest for those under age 40 (10.59%), followed by age groups 40 to 59 (10.45%), and 
60+ (5.67%). Prevalence by race was also examined: Native American (10.38%), Black 
(9.73%), White (7.82%), Hispanic (7.78%) and Asian (6.06%). Higher asthma preva-
lence rates were observed for female (8.69%) compared to male patients (7.28%). 
Geographic variation was analyzed with the highest asthma prevalence observed 
in Missouri (14.04%), followed by New Hampshire (13.84%), Connecticut (13.12%), 
Ohio (12.96%) and Minnesota (12.52%). Prevalence rates were found to be highest in 
the Midwest (10.43%) compared to the Northeast (8.65%), West (6.96%) and Southern 
(6.39%) U.S. regions. cOnclusiOns: The current study shows that patients under 
age 60 have a higher probability of being diagnosed with asthma. Moreover, Native 
American and Black patients were more likely to be diagnosed with asthma com-
pared to other races. Geographically, patients residing in the Midwest U.S. region 
have a higher risk for an asthma diagnosis.
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Objectives: There is a huge burden of disease for childhood asthma and aller-
gies. Evidence on migration as a potential risk factor for asthma and allergies is 
contradictory; therefore, we aimed at assessing the international evidence for the 
association between migration status and asthma and allergies. MethOds: We 
conducted a systematic review on asthma and allergies and immigration status in 
accordance with the guidelines set by the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) statement. The search was conducted in the 
PubMed database in November 2012 and we chose broad string and MeSH terms 
in our search to include any definition of asthma and allergies, and migration sta-
tus. From the total of 2737 unique hits identified through the search, 127 studies 
were selected for a full-text review. After reviewing full-text papers, 54 studies were 
selected for data extraction and synthesis. Results: The prevalence of asthma 
and allergies in newly arrived immigrants appeared to be similar to prevalences 
PRS10
analySiS Of OxaliPlatin-indUCed alleRgiC ReaCtiOnS and the 
effeCtiveneSS Of ReCeiving PReventive antihiStamine dRUgS
Wu J.S.1, Kou H.S.2, Wang H.Y.1
1Chi-Mei medical center, Tainan, Taiwan, 2Kaohsiung Medical University, Kaohsiung, Taiwan
Objectives: Oxaliplatin is currently one of the main cytotoxic drugs for some 
cancers. In recent years, increasing incidence of oxaliplatin-induced allergic reac-
tions was reported. Severe allergic reactions even interrupted ongoing oxaliplatin 
treatments. Many doctors give the patients preventive antihistamine drugs before 
oxaliplatin infusions. However, on the one side, antihistamine drugs often cause 
dizziness or conscious disturbance. On the other side, antihistamine drugs cannot 
prevent some patients effectively from oxaliplatin-induced allergic reactions by 
clinical observation. MethOds: This is a retrospective case-control study. Patients 
receiving oxaliplatin from 2008 to 2013 in a medical center in southern Taiwan were 
included and divided into two groups. The study group consisted of patients without 
taking antihistamine drugs before oxaliplatin infusions; the control group consisted 
of patients taking antihistamine drugs before oxaliplatin infusions. We analyzed the 
incidence and the grade of oxaliplatin-induced allergic reactions and the cost of 
antihistamine drugs. The data was analyzed by SPSS 19.0. Results: There were 535 
patients included for analysis. There were 164 patients in the study group, and 371 
patients in the control group. Allergic reactions happened to 27 patients (16.46%) in 
the study group, while 58 patients (15.22%) in the control group (95% CI: 0.571-1.548; p 
> 0.05). 15 patients (9.15%) had mild allergic reactions and 12 patients (7.32%) moder-
ate and severe in the study group; 36 patients (9.7%) had mild allergic reactions and 
22 patients (5.93%) moderate and severe in the control group (95% CI: 0.303-1.928; p 
> 0.05). The cost of antihistamine drugs and consumables was about NTD 56,000 per 
year. cOnclusiOns: This study reveals that the effectiveness of giving antihistamine 
drugs to prevent oxaliplatin-induced allergic reactions had no statistically significant 
difference from that in the control group. Preventive antihistamine drugs not only 
cause dizziness or conscious disturbance but also increase the cost of treatments.
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Objectives: Children with Down syndrome (DS) are at significant risk for res-
piratory tract (RTI) and respiratory syncytial virus (RSV) infection and related 
hospitalization. We compared hospitalization rates for RTI in DS children aged < 
2 years who prospectively received palivizumab during the RSV season versus a 
previously published, similar untreated DS birth cohort. MethOds: 532 prophy-
laxed DS children were assembled from the prospective Canadian palivizumab 
registry (CARESS) between the years 2005-2012. The untreated group comprised 
233 DS children derived from a Dutch, nation-wide birth cohort from 2003-2005. 
Events during the RSV seasons were counted. Demographics and risk factors were 
compared using t-test or chi-square where appropriate. Poisson regression analy-
sis was performed to compare incidence rate ratios [95% CI] for both RTI and con-
firmed RSV hospitalization between the groups while controlling for observation 
length and known risk factors for severe RSV infection. Results: In total, 31 (23 
untreated, 8 treated) RSV-related hospitalizations were documented. The adjusted 
risk of RSV-related hospitalizations was higher in untreated subjects compared 
to palivizumab recipients (incidence rate ratio 3.63 [95% CI: 1.52-8.67], p= 0.004). 
The adjusted risk for hospitalization for all respiratory tract infection (147 events; 
73 untreated, 74 treated) was similar (incidence rate ratio untreated versus pal-
ivizumab 1.11 [0.80 – 1.55], p= 0.53). cOnclusiOns: These results suggest that 
palivizumab is associated with a 3.6-fold reduction in the incidence rate ratio for 
RSV-related hospitalization in children with DS aged < 2 years. A randomized trial 
is needed to determine the efficacy of RSV immunoprophylaxis in this specific 
high risk patient population.
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Objectives: Other Interstitial pulmonary diseases with fibrosis (OIPDF) classified 
by ICD-10 CA code J84.1 are rare with unknown prevalence at the national level 
in Canada. OIPDF includes diffuse pulmonary fibrosis, fibrosing alveolitis (crypto-
genic), Hamman-Rich syndrome, idiopathic pulmonary fibrosis, and usual intersti-
tial pneumonia. To estimate the prevalence and incidence of OIPDF in Canada in 
2010. MethOds: We used mandatory standardized national administrative data from 
fiscal years 2006 to 2011 to identify OIPDF cases aged 50+ with an ICD-10 CA diagnosis 
code of J84.1 from acute care admissions, emergency room visits, day surgery and 
in-hospital respiratory clinics. Cases were required to have computed tomography, 
biopsy or bronchoscopy prior to the OIPDF diagnosis and were excluded if they had a 
subsequent diagnosis of other interstitial lung disease after the OIPDF diagnosis. We 
compared the rates of prevalence to incidence and investigated the rates of death 
with Kaplan Meier analysis. National estimates for rates of prevalence and risk of 
death were compared for OIPDF versus COPD. Results: In Canada for the year 2010 
for ages 50+, the prevalence of OIPDF was 6,307 (54.1/100,000) and incidence was 2,804 
cases (24.0/100,000). The low ratio of prevalence to incidence (2.2) existed because of a 
high death rate, with the 4 year cumulative risk of death being 46.8%. The number of 
deaths for OIPDF was 28.9% of all deaths from COPD, while the prevalence of OIPDF 
was 2.9% of all COPD cases. cOnclusiOns: OIPDF is an important disease with a 
high death rate and non-trivial prevalence and incidence rates. However, there were 
wide variations in the rates of prevalence and incidence across the provinces, and the 
